1 June
2010
Research: Zonnic nicotine mouth spray and lozenge effective in relieving
cravings: published
McRobbie H, Thornley S, Bullen C, Lin R-B,
Senior H, Laugesen M, Whittaker R, Hayek P. A randomized trial of the
effects of two novel nicotine replacement therapies on tobacco withdrawal
symptoms and user satisfaction.
Published in Addiction On line 14 May 2010 ahead of print.
Abstract at www.pubmed.org PMID 20491724
Comment Despite having researched these nicotine products in
NZ, NZ’s small market does not get priority for early sale here.
The Zonnic mouthspray, on sale in Sweden, is being trialled
(recruiting now) during 2010 in Christchurch and Wellington by University of Otago (Prof Julian Crane and Dr
Caldwell brent.caldwell@otago.ac.nz
), for its ability to help people stop smoking.
__________________________________________________________________________________________________
17 May 2010
Pulmonary delivery of Nicotine Pyruvate: Pharmacokinetic and
Sensory Characteristics
In Experimental & Clinical Psychopharmacology journal:
For publication soon: Accepted
Jed E. Rose, James E. Turner, Thangaraju
Murugesan, Frederique M. Behm, and Murray Laugesen
An
advance on the e-cigarette, in that
nicotine is absorbed rapidly via the lung.. See below under March 2010 for more
information.
__________________________________________________________________________________________________
14 May 2010
Oral submission to the Maori Affairs Select
Committee Inquiry into the Tobacco Industry
from Health New Zealand Ltd: Summarises
company research relevant to the Inquiry. (Powerpoint slideshow). more....
_________________________________________________________________________________________________
14 May 2010
Four policies to end sales of cigarettes and
smoking tobacco in New
Zealand by 2020:published
NZ Medical Journal 14 May 2010. http://www.endsmoking.org.nz/FourPolicies14May2010.pdf
________________________________________________________________________________________________________
17
April 2010 NZ Herald
Medical
rules lead to withdrawal of electronic quit-smoking aid
http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=10638910 An online pharmacy recalls nicotine
ecigarettes
15 April 2010 NZ Herald
Smoker wants e-ciggie nicotine
in a shop near him
http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=10638418 An ecigarette fan was once a very heavy
smoker.
Newswire 13 April 2009
Health campaigner: The e-ciggie a
step towards ending nicotine’s evil
Virginia
McMillan. Interview with Dr Murray Laugesen: 25 years working on smoking,
50 years in medicine.
http://www.newswire.co.nz/2010/04/health-campaigner-e-ciggies-a-step-towards-ending-nicotines-evil/
________________________________________________________________________________________________
NZ Herald 13 April 2009
E-ciggie may help smokers to quit
http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=10638017
NZ E-cigarette trial Tob
Control 2010;19:98-103 doi:10.1136/tc.2009.031567
published 9 April 2009
The
electronic cigarette is effective in raising plasma nicotine levels, and in
reducing cravings, and is more pleasant to use than the medicinal nicotine
inhaler…………….
Effect of an electronic nicotine delivery
device (e cigarette) on desire to smoke and withdrawal, user preferences
and nicotine delivery: randomised cross-over trial
C Bullen1, H McRobbie2, S Thornley3, M Glover4, R Lin5, M Laugesen6 Full text as pdf
Abstract
Objectives To measure the short-term effects of
an electronic nicotine delivery device (“e cigarette”, ENDD) on
desire to smoke, withdrawal symptoms, acceptability, pharmacokinetic
properties and adverse effects.
Design Single blind randomised repeated
measures cross-over trial of the Ruyan V8 ENDD.
Setting University research
centre in Auckland, New Zealand.
Participants 40 adult dependent
smokers of 10 or more cigarettes per day.
Interventions Participants were
randomised to use ENDDs containing 16 mg nicotine or 0 mg
capsules, Nicorette nicotine inhalator or their usual cigarette on each of
four study days 3 days apart, with overnight smoking abstinence before
use of each product.
Main outcome measures The primary
outcome was change in desire to smoke, measured as “area under the
curve” on an 11-point visual analogue scale before and at intervals
over 1 h of use. Secondary outcomes included withdrawal symptoms,
acceptability and adverse events. In nine participants, serum nicotine
levels were also measured.
Results Over 60 min,
participants using 16 mg ENDD recorded 0.82 units less desire to smoke
than the placebo ENDD (p=0.006). No difference in desire to smoke was found
between 16 mg ENDD and inhalator. ENDDs were more pleasant to use than
inhalator (p=0.016) and produced less irritation of mouth and throat
(p<0.001). On average, the ENDD increased serum nicotine to a peak of
1.3 ng/ml in 19.6 min, the inhalator to 2.1 ng/ml in
32 min and cigarettes to 13.4 ng/ml in 14.3 min.
Conclusions The 16 mg Ruyan
V8 ENDD alleviated desire to smoke after overnight abstinence, was well
tolerated and had a pharmacokinetic profile more like the Nicorette
inhalator than a tobacco cigarette. Evaluation of the ENDD for longer-term
safety, potential for long-term use and efficacy as a cessation aid is
needed.
The trial was funded by Ruyan the manufacturer, through Health New
Zealand Ltd as the NZ sponsor, and carried out by Clinical Trials Research
Unit, University of Auckland.. Ruyan, the funder, had no influence on the
design, analysis, results or conclusions.
Revised 13 April 2010
Critique of WHO Tobacco Regulation Committee report on electronic
cigarettes
Health New Zealand Ltd sees potential in e-cigarettes, while WHO
group sees them as a threat
TobRegCritique.doc
___________________________________________________________________________________________
1
March 2010
New nicotine cigarette gives rapid lung
delivery of nicotine
After tests in Christchurch in 2009, this product is now ready for
commercialization as a smoking substitute or as a stop smoking
medicine
SRNT 2010_
PosterAbstract_ Rose.doc
This device was tested by Health New Zealand
Ltd Christchurch NZ and Christchurch Clinical Studies Trust, for Duke
University (the patent holders), in 2009 on nine healthy smokers. Results
were announced by Principal Investigator Dr Jed Rose, of Duke University at
the 16th Annual Conference of the Society for Research on
Nicotine and Tobacco (SRNT), Baltimore, Maryland, USA on 27 February 2010.
Turner, a co-inventor of the nicotine inhaler; and Dr Raju Murugesan, a
pharmacologist at Duke. Dr Laugesen and Dr Chris Wynne of Christchurch
Clinical Studies Trust were co-authors for this paper, entitled Pulmonary delivery of Nicotine
Pyruvate: Pharmacokinetic and Sensory Characteristics
Dr Laugesen and Dr Chris Wynne of Christchurch
Clinical Studies Trust were co-authors for this paper, entitled
The inventors are Dr Jed Rose, a neuroscientist
at Duke; his brother Dr Seth Rose, an organic chemistry professor; Dr Jim
Pulmonary
delivery of Nicotine Pyruvate: Pharmacokinetic and Sensory Characteristics
The device depends on a chemical reaction at room
temperature, with no heating or lighting up. The nicotine pyruvate
cigarette will reach the market in 3 to 5 years time. It is yet to be
manufactured and miniaturized down to the size of a tobacco cigarette. It
is not an electronic cigarette. The smoker only inhales one molecule
– nicotine pyruvate, which dissolves into nicotine and pyruvate on
reaching the lungs.
Pyruvate is a normally found in the blood, and inhaling
NP is not expected to raise this level appreciably
.
